Best practice and recommended strategy for facing the peculiar challenges of the Brazilian patent system in the Pharma and Biotech Sectors
- 09 September 2015
- Articles
With a population of more than 200 million people and being the 6th pharmaceutical market in the world, Brazil is a top priority for patent investments in the pharma and biotech industry.
Applicants, however, face several obstacles when prosecuting in Brazil, especially in cases involving pharmaceutical products and processes.
The huge backlog together with the juridical insecurity caused by the two-tier examination of the Brazilian PTO and ANVISA (Brazilian Food and Drug Agency), both with recently appointed presidents, are some of the many aspects that require a solid strategy and good advice for maximizing patent protection in Brazil.
Topics that we will cover:
– Introduction: Basic facts about Brazilian pharma and biotech market
– Fighting the Backlog: strategy to accelerate the granting of patents
– Industry Spotlight: pharma patents & ANVISA
Twitter
Linkedin